Retrospective Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Jun 16, 2022; 10(17): 5606-5619
Published online Jun 16, 2022. doi: 10.12998/wjcc.v10.i17.5606
Table 1 General features of patients with hepatic epithelioid hemangioendothelioma
General feature
No. of patients
%
Presence of symptoms, n = 254
Asymptomatic6927.2
Symptomatic18572.8
Epigastric pain9939.0
Hepatosplenomegaly3915.4
Inappetence3413.4
Abdominal distension3112.2
Weight loss2710.6
Fatigue2610.2
Epigastric discomfort259.8
Hydrothorax and ascite187.1
Fever124.7
Jaundice249.4
Thoracalgia and humeral back pain207.9
Nausea and vomiting103.9
Edema83.1
Cough and expectoration93.5
Abdominal mass20.8
Hematemesis and melena20.8
Intrahepatic involvement type, n = 197
Multinodular type (including diffuse type)16885.3
Mononodular type2914.7
Type of involvement, n = 197
Intrahepatic involvement12965.5
Extrahepatic involvement6834.5
Lung4422.3
Lymph node115.6
Bone136.6
Peritoneum73.6
Spleen105.1
Pleura42.0
Omentum21.0
Liver function, n = 157
Normal8956.7
Abnormal6843.3
Elevated ALT in U/L4025.5
Elevated AST in U/L4025.5
Elevated TBIL in μmol/L2415.3
Elevated ALP in U/L4327.4
Elevated GGT in U/L3220.4
Tumor markers
Elevated AFP in ng/mL8/1714.7
Elevated CEA in ng/mL7/1305.4
Elevated CA19-9 in U/mL13/1359.6
Elevated CA125 in U/mL14/5326.4
Plain CT scan, n = 198
Low density lesions195/19898.6
High density or uneven density lesions3/1981.4
Calcification30/19815.2
Capsular retraction34/19817.2
Confluent masses42/19821.2
Contrast-enhanced CT, n = 163
Tumor edge enhancement138/16384.7
Tumor edge without enhancement25/16315.3
Target sign33/16320.2
Lollipop sign19/16311.7
Immunohistopathological markers
FVIII-RAg117/11899.2
CD34215/21898.6
CD31171/17398.8
Vimentin94/9598.9
SMA12/2744.4
Desmin0/13NA
Hepatocyte8/5813.8
CK38/8146.9
EMA6/3417.6
AFP0/34NA
CEA0/11NA
S-1001/339.1
D2-407/1163.6
Genetics
YAP1-TFE33/475.0
WWTR1-CAMTA13/560.0